Dyax Corp. Announces Issuance Of Two Key U.S. Patents For DX-2930
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents related to DX-2930, an investigational fully human monoclonal antibody inhibitor of active plasma kallikrein. One patent, assigned U.S. Patent No. 8,816,055, contains claims covering the specific sequence of DX-2930, and the other, assigned U.S. Patent No. 8,822,653, contains claims covering monoclonal antibodies that bind to the active form of human plasma kallikrein and do not bind human pre-kallikrein. Both patents are expected to provide coverage for DX-2930 until at least 2032.
Help employers find you! Check out all the jobs and post your resume.